What was the primary endpoint of the ALLEGRO-2b/3 trial for ritlecitinib?

Featuring E. James Song, MD, FAAD | Co-Chief Medical Officer and Director of Clinical Research, Frontier Dermatology,Mill Creek, WA | Published October 01, 2024